Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 3Unknown 1Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 116Gastrointestinal 35Sarcoma 6Lymphoid 6Thoracic 4Other solid neoplasm 4Gynecologic 4Tumor-Agnostic 3Genitourinary 3Other hematologic neoplasm 2Head & Neck 1Dermatologic 1CNS 1

Conditions

Neoplasms 2Adenocarcinoma 1

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Epirubicin × Tumor-Agnostic × Clear all
NCT01869192 2019-09-24

Phase II Trial for Large ER-Negative Breast Cancers

University of Colorado, Denver

Phase 2 Completed
72 enrolled 6 charts
Tumor-Agnostic

Neoplasms

NCT00246103 2017-02-23

Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
82 enrolled
Tumor-Agnostic

Neoplasms

NCT00140075 2011-05-26

Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer

Pfizer

Phase 3 Completed
606 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡